好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in a patient with Sjogren's Syndrome: A Case Report and Literature Review
Autoimmune Neurology
P12 - Poster Session 12 (11:45 AM-12:45 PM)
8-006
To report a case of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a patient with Sjogren's Syndrome (SS), and to perform a literature review examining cases of concurrent MOGAD and SS.
Few cases of co-occurrent MOGAD and SS have been reported, and the clinical significance of comorbid SS in patients with MOGAD remains poorly understood.
A PubMed search was performed using the following terms: “((myelin oligodendrocyte glycoprotein) OR (MOG) OR (MOGAD)) AND ((Sjogren's) OR (Sjogrens) OR (Sjo篓gren's) OR (Sjo篓grens)).”

A 30-year-old woman first presented with acute disseminated encephalomyelitis (ADEM) at age 4. Over the next 18 years, she experienced over 10 relapses (involving unilateral or bilateral optic neuritis [ON], brainstem syndromes, and one cerebral syndrome) before achieving remission with intravenous immunoglobulin G. At age 16, she tested positive for serum anti-MOG antibodies. She was later diagnosed with psoriasis and SS.

Literature review identified four additional patients (three [75%] female) with concurrent MOGAD and SS, who ranged in age from 13-45 years at neurologic presentation. MOGAD syndromes included ON in two (50%) patients: one with longitudinally extensive ON, and one with bilateral ON then unilateral ON several years later. Two (50%) patients had transverse myelitis: one was longitudinally extensive, and the other involved the conus. Three (75%) patients had monophasic courses at 1-6 years of follow-up, while one (25%) patient experienced one relapse. Acute treatment involved steroids in all four cases, with the addition of PLEX in one case. Only one patient was treated with chronic immunotherapy (one year of azathioprine). Though our patient developed permanent visual deficits, outcomes in the other patients were favorable.

This review identified five patients with concurrent SS and MOGAD, whose neurologic presentations and treatment responses were characteristic of MOGAD. These cases suggest that when present, comorbid SS does not significantly alter the course of MOGAD.
Authors/Disclosures
Mattia Wruble, MD
PRESENTER
The institution of Dr. Wruble has received research support from Alexion. The institution of Dr. Wruble has received research support from Roche.
Rebecca Salky Rebecca Salky has nothing to disclose.
Tanuja Chitnis, MD, FAAN (Brigham and Women's Hospital) Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Chitnis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche-Genentech. Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octave Biosciences. Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. The institution of Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Chitnis has received research support from Novartis. The institution of Dr. Chitnis has received research support from Sanofi. The institution of Dr. Chitnis has received research support from Octave. The institution of Dr. Chitnis has received research support from Genentech-Roche. The institution of Dr. Chitnis has received research support from Tiziana Life Sciences. The institution of Dr. Chitnis has received research support from Bristol-Myers Squibb. The institution of Dr. Chitnis has received research support from Wesley Clover.
Michael Levy, MD, PhD, FAAN (Massachusetts General Hospital/Harvard Medical School) Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Pharma. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Levy has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various law firms. The institution of Dr. Levy has received research support from National Institutes Health.
Shamik Bhattacharyya, MD, FAAN (Brigham and Women's Hospital) Dr. Bhattacharyya has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NeuroLambda. Dr. Bhattacharyya has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharmaceuticals. Dr. Bhattacharyya has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Bhattacharyya has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Bhattacharyya has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Continuum. Dr. Bhattacharyya has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wiley. Dr. Bhattacharyya has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Merck. The institution of Dr. Bhattacharyya has received research support from Alexion Pharmaceuticals. The institution of Dr. Bhattacharyya has received research support from National Institute of Health. The institution of Dr. Bhattacharyya has received research support from UCB. The institution of Dr. Bhattacharyya has received research support from Genentech. Dr. Bhattacharyya has received publishing royalties from a publication relating to health care. Dr. Bhattacharyya has received publishing royalties from a publication relating to health care.